Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd held its 36th Annual General Meeting on September 30, 2025 at Ginger Hotel, Indore, with all four resolutions passed with the required majority. Resolution 1 (adoption of audited financial statements for FY ended March 31, 2025) was approved with 97.14% votes in favour (22,75,426 shares from 61 members). Resolution 2 (re-appointment of Mr. Kuniamuthur Nanjappan Anand as director retiring by rotation) passed with 96.02% in favour. Resolutions 3 and 4 were special resolutions — approval of remuneration payable to Mr. Nanjappan Anand (96.02% in favour) and appointment of Mr. Tanuj Jain Susilkumar as Secretarial Auditor for a 5-year term (97.14% in favour). The vote of Mr. Nanjappan Anand (holding 6,58,500 shares) was declared invalid for Resolutions 2 and 3 as he was an interested party. E-voting was conducted through CDSL and scrutinised by CS Jay Arvind Jain of Jay Jain & Associates.
All AGM resolutions passed comfortably with over 96% approval, indicating strong shareholder support for management proposals including director re-appointment, executive remuneration, and secretarial auditor appointment. No material governance disputes or significant dissent that would concern retail investors.